SPY—QQQ674.25−0.83%BTC/USD65,833.44−3.52%DIA521.21−0.37%GLD355.70+0.07%TLT79.42+0.05%

Corvus Pharmaceuticals Inc

CRVSNASDAQ

Trade with Public

$10.64

0.020.19%

At close: Nov 13, 4:00 PM EST

$10.71

0.070.66%

After Hours: 5:55 PM EST

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Corvus Pharmaceuticals (CRVS) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Corvus Pharmaceuticals (CRVS) stock.

Analyst Consensus — 8 Analysts

7Buy

1Hold

# Analysts8

Latest Upgrades and Downgrades for Corvus Pharmaceuticals Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Goldman Sachs	Paul Choi	Initiate	Buy	$40
—	Oppenheimer	Jeff Jones	PT Raise	Outperform	$32→$33
—	Jefferies	Roger Song	PT Raise	Buy	$13→$42
—	Oppenheimer	Jeff Jones	PT Raise	Outperform	$15→$32
—	Barclays	Etzer Darout	PT Raise	Overweight	$16→$28
—	HC Wainwright & Co.	Sean Lee	PT Raise	Buy	$11→$27
—	Barclays	Etzer Darout	Initiate	Overweight	$16
—	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$12→$11
—	Oppenheimer	Jeff Jones	PT Raise	Outperform	$15→$17
—	Oppenheimer	Jeff Jones	PT Raise	Outperform	$14→$15
—	HC Wainwright & Co.	Sean Lee	Maintained	Buy	$11
—	HC Wainwright & Co.	Sean Lee	Maintained	Buy	$11
—	HC Wainwright & Co.	Sean Lee	Initiate	Buy	$11
—	Oppenheimer	Jeff Jones	PT Raise	Outperform	$8→$14
—	Mizuho	Graig Suvannavejh	Upgrade	Neutral→Outperform	$4→$12
—	Ladenburg Thalmann	Aydin Huseynov	PT Raise	Buy	$12→$21
—	Oppenheimer	Jeff Jones	PT Raise	Outperform	$7→$8
—	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	—
—	Mizuho	Graig Suvannavejh	Maintained	Neutral	$4
—	Oppenheimer	Jeff Jones	PT Cut	Outperform	$8→$7

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) Stock Price Target 2026

Latest Upgrades and Downgrades for Corvus Pharmaceuticals Stock

Corvus Pharmaceuticals (CRVS) Stock Price Target 2026

Latest Upgrades and Downgrades for Corvus Pharmaceuticals Stock

Analyst Ratings News

PRO
Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

PRO
Jefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

PRO
Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

PRO
Barclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

PRO
Jefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

PRO
Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

PRO
Barclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) Stock Price Target 2026

Latest Upgrades and Downgrades for Corvus Pharmaceuticals Stock

Corvus Pharmaceuticals (CRVS) Stock Price Target 2026

Latest Upgrades and Downgrades for Corvus Pharmaceuticals Stock

Analyst Ratings News

PROWatching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PROGoldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

PROJefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

PROOppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

PROBarclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28

People Also Watch

People Also Watch

Analyst Ratings News

PROWatching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PROGoldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

PROJefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

PROOppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

PROBarclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28

PRO
Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

PRO
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

PRO
Jefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

PRO
Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

PRO
Barclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28

PRO
Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

PRO
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

PRO
Jefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

PRO
Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

PRO
Barclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28